Herpesvirus-mediated systemic delivery of nerve growth factor

Molecular Therapy

Volumn 3, Issue 1, 2001, Pages 61-69

  Wolfe, Darren ^a   Goins, William F ^a   Kaplan, Theodore J ^a   Capuano, Saverio V ^a   Fradette, Julie ^a   Murphey Corb, Michael ^a   Robbins, Paul D ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; HSV vector; Intra articular; NGF; Patellar ligament

Indexed keywords

GENE PRODUCT; NERVE GROWTH FACTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EPIDERMIS; EVALUATION; FOOT PAD; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; INNERVATION; INOCULATION; INTRAARTICULAR DRUG ADMINISTRATION; JOINT; LAVAGE; MACACA; NONHUMAN; PATELLA LIGAMENT; PHEOCHROMOCYTOMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RABBIT; REPORTER GENE; RHESUS MONKEY; SYSTEMIC DISEASE; TIME; TRANSGENE; VIRUS GENOME; VIRUS REPLICATION;

ANIMALIA; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MACACA; MACACA MULATTA; ORYCTOLAGUS CUNICULUS;

EID: 0034986411     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0225     Document Type: Article

References (83)

1. Circulating human factor IX produced in keratin-promoter transgenic mice: A feasibility study for gene therapy of haemophilia B
2. Nerve growth factor prevents experimental cisplatin neuropathy
3. Neurotrophic factors in the therapy of peripheral neuropathy
4. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy
5. Continuous infusion of interleukin-1 beta induces a nonthyroidal illness syndrome in the rat
6. Genetic transfer of the wobbler gene to a C57BL/6J × NZB hybrid stock: Natural history of the motor neuron disease and response to CNTF and BDNF cotreatment
7. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration
8. Systematic delivery of peptides and proteins across absorptive mucosae
9. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis
10. Systemically but not orogastrically delivered insulin-like growth factor (IGF)-I and long [Arg3]IFG-I stimulates intestinal disaccharidase activity in two age groups of suckling rats
11. Distribution and metabolism patterns of plasma 7S- and beta-NGF in the adult male rat
12. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats
13. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials
14. Therapeutic potential of the neurotrophins and neurotrophin-CNF combinations in peripheral neuropathies and motor neuron diseases
15. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile
16. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects
17. Intraventricular infusion of nerve growth factor as the cause of a sympathetic fiber sprouting in sensory ganglia
18. Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells
19. Human studies of recombinant human nerve growth factor and diabetic peripheral neuropathy
20. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management
21. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population
22. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats
23. Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration
24. Genetically modified PC12 brain grafts: Survivability and inducible nerve growth factor expression
25. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
26. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle
27. Development of herpes simplex virus replication defective multigene vectors for combination gene therapy applications
28. Engineering herpes simplex virus vectors for CNS applications
29. Deletion of multiple immediate early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons
30. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins
31. Physical state of the latent herpes simplex virus genome in a mouse model system: Evidence suggesting an episomal state
32. RNA from an immediate early region of the HSV-1 genome is present in the trigeminal ganglia of latently infected mice
33. RNA complementary to a herpesviruses a gene mRNA is prominent in latently infected neurons
34. Two herpes simplex virus type-1 latency active promoters differ in their contribution to latency-associated transcript expression during lytic and latent infection
35. In vivo deletion analysis of the herpes simplex virus type 1 latency-associated transcript promoter
36. L flanking repeats
37. Evidence for herpes simplex viral latency in the human cornea
38. Tissue-specific accumulation of latency-associated transcripts in herpes virus-infected rabbits
39. Detection of herpes simplex virus type 1 latency-associated transcript expression in trigeminal ganglia by in situ reverse transcriptase PCR
40. Retention of herpes simplex virus DNA sequences in the nuclei of mouse footpad keratinocytes after recovery from primary infection
41. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglia neurons from peroxide toxicity
42. Herpes simplex virus type 1 vector mediated gene transfer to muscle
43. Progress in the development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis
44. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo
45. Intra-articular delivery of a herpes simplex virus IL-1 Ra gene vector reduces inflammation in a rabbit model of arthritis
46. Gene transfer to neurons using herpes simplex virus-based vectors
47. Enhanced tumor-cell killing in the presence of ganciclovir by HSV-1 vector-directed co-expression of human TNF-α and HSV thymidine kinase
48. HSV vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine induced degeneration of neurons in the substantia nigra in vivo
49. Expression of β-galactosidase in neurons of dorsal root ganglia which are latently infected with herpes simplex virus type 1
50. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus
51. Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4
52. Anti-viral activity of herpes simplex virus vectors expressing alpha-interferon
53. Induction of neurite outgrowth by interleukin-6 is accompanied by activation of Stat3 signaling pathway in a variant PC12 cell (E2) line
54. Development of a high-throughout quantitative assay for detecting herpes simplex virus DNA in clinical samples
55. An unbiased method for estimation of total epidermal nerve fibre length
56. Utilization of the herpes simplex virus type 1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system
57. Intraepidermal nerve fiber density in patients with painful sensory neuropathy
58. Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy
59. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo
60. Recombinant adeno-associated virus for muscle directed gene therapy
61. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
62. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
63. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats
64. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
65. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscle
66. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
67. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
68. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
69. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors
70. Adeno-associated virus as a vector for liver-directed gene therapy
71. Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA
72. Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10
73. Gene therapy for diabetes mellitus in rats by hepatic expression of insulin
74. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
75. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin
76. Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy
77. Autonomous parvovirus transduction of a gene under control of tissue-specific inducible promoters
78. Control of parvovirus DNA replication by a tetracycline-regulated repressor
79. The nerve growth factor 35 years later
80. Nerve growth factor administration protects against experimental diabetic sensory neuropathy
81. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. II. A conditioning lesion paradigm
82. Neurotrophic agents may exacerbate the pathologic cascade of Alzheimer's disease
83. Effect of long-term nerve growth factor treatment on body weight, blood pressure, and serum corticosterone in rats